comparemela.com

Latest Breaking News On - Committee on addressing sickle cell disease - Page 2 : comparemela.com

Emmaus Life Sciences Reports Q2 2023 Financial Results

/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.

Saudi arabiaUnited statesUnited arab emiratesKingdom of saudi arabiaWillis leeYutaka niiharaDrug administrationExchange commission onPrnewswire emmaus life sciences incNational center on birth defectsCenters for diseaseEmmaus life sciences incCommittee on addressing sickle cell diseaseBlueprint for action national academy of sciencesEmmaus life sciencesCompany contact

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing.

United arab emiratesUnited statesSaudi arabiaKingdom of saudi arabiaYutaka niiharaWillis leeGeorge sekulichExchange commissionEmmaus life sciences incOman ministry of healthCompany contactCenters for diseaseEmmaus life sciencesGlobal commercialization of emmaus life sciences incNational center on birth defectsCommittee on addressing sickle cell disease

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman - Emmaus Life Sciences (OTC:EMMA)

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX:EMMA), a leader in sickle cell disease treatment, today

Saudi arabiaUnited arab emiratesUnited statesKingdom of saudi arabiaYutaka niiharaWillis leeGeorge sekulichBlueprint for action national academy of sciencesNational center on birth defectsCommittee on addressing sickle cell diseaseExchange commissionCenters for diseaseEmmaus life sciencesCompany contactGlobal commercialization of emmaus life sciences incPrnewswire emmaus life sciences inc

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Sickle Cell Disease Treatment Commercially Available in Five GCC Countries TORRANCE, Calif., July 13, 2023 /PRNewswire/ Emmaus Life Sciences, Inc. , a leader in sickle cell disease treatment,.

United arab emiratesSaudi arabiaUnited statesKingdom of saudi arabiaGeorge sekulichYutaka niiharaWillis leeEmmaus life sciencesExchange commissionPrnewswire emmaus life sciences incBlueprint for action national academy of sciencesCenters for diseaseOman ministry of healthNational center on birth defectsGlobal commercialization of emmaus life sciences incCompany contact

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.

United statesSaudi arabiaUnited arab emiratesKingdom of saudi arabiaYutaka niiharaGeorge sekulichWillis leeNational center on birth defectsExchange commissionEmmaus life sciences incBlueprint for action national academy of sciencesGlobal commercialization of emmaus life sciences incCommittee on addressing sickle cell diseaseCenters for diseaseEmmaus life sciencesCompany contact

vimarsana © 2020. All Rights Reserved.